Shah Yash B, Krishnan Akshay S, Goldberg Zachary N, Jayanti Varun, Harness Erika D, Nash David B
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA.
College of Population Health, Thomas Jefferson University, Philadelphia, USA.
Cureus. 2025 Apr 15;17(4):e82328. doi: 10.7759/cureus.82328. eCollection 2025 Apr.
The recent growth and integration of artificial intelligence (AI) into medical products have the potential to revolutionize surgical care. The private sector is largely responsible for this innovation. We aimed to characterize the growth, aims, and finances of private industry AI solutions within surgery.
An initial search using the CB Insights market intelligence platform returned 126 private companies; 20 met the exclusion criteria. Three independent reviewers extracted variables of interest, including company demographics, product classification, surgical subspecialty of interest, funding, valuation, and acquisition status. Product purpose and functionality were characterized in detail.
The first company was founded in 2003, with 50% (n=53) founded between 2015 and 2019. General surgery (n=57) and orthopedics (n=21) were the most common surgical subspecialties. The most common product categories were intraoperative image analysis (n=25), aiming to improve the visualization or navigation of the surgical site, and diagnostic imaging (n=18), aiming to improve the efficiency and accuracy of diagnosis and surgical planning. Of note, 12 companies aimed to increase the autonomy of surgical robotics. Finances were notably right-skewed, and total industry valuation exceeded one billion dollars, while six companies had been acquired.
There are numerous companies implementing AI solutions, and financial investment is high. Given the rapid pace of development, surgeon input is needed to reconcile product development with patient-centered care. Clinician participation in private industry development may address health inequities, shape the future role of surgeons in the operating room, and ensure safeguards with regulatory oversight and improved data reporting.
近期人工智能(AI)在医疗产品中的发展与整合,有可能给外科护理带来变革。私营部门在很大程度上推动了这一创新。我们旨在描述外科领域私营企业人工智能解决方案的发展、目标和资金情况。
使用CB Insights市场情报平台进行初步搜索,共返回126家私营公司;20家不符合纳入标准。三名独立评审员提取了相关变量,包括公司概况、产品分类、感兴趣的外科亚专业、资金、估值和收购状况。详细描述了产品目的和功能。
第一家公司成立于2003年,50%(n = 53)的公司在2015年至2019年期间成立。普通外科(n = 57)和骨科(n = 21)是最常见的外科亚专业。最常见的产品类别是术中图像分析(n = 25),旨在改善手术部位的可视化或导航,以及诊断成像(n = 18),旨在提高诊断和手术规划的效率与准确性。值得注意的是,有12家公司旨在提高手术机器人的自主性。资金明显呈右偏态分布,行业总估值超过十亿美元,有六家公司已被收购。
有众多公司在实施人工智能解决方案,且金融投资规模较大。鉴于发展速度较快,需要外科医生的参与,以使产品开发与以患者为中心的护理相协调。临床医生参与私营企业的发展,可能有助于解决健康不平等问题,塑造外科医生在手术室中的未来角色,并通过监管监督和改进数据报告确保安全保障。